EUVIMEDEUVIMED entdecken
Crossref

Translation of a novel EphA2-targeted PET tracer from preclinical models to first-in-human studies in pancreatic cancer

Xinyu Liu, Li Sun, Jialiang Lei, Liyan Bai, Haoyao Guo, Yichong Fang, Jianping Zhang, Chunjuan Jiang, Xiaoping Xu, Shaoli Song

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-07966-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Xinyu Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, No. 270 Dong'an Road, Xuhui District, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Receptor, EphA2, Pancreatic Neoplasms, Positron Emission Tomography Computed Tomography, Radiopharmaceuticals. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Shanghai Oriental Talents Program Youth Project, National Natural Science Foundation of China, Key Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Ephrin type-A receptor 2 (EphA2) is a promising target in pancreatic ductal adenocarcinoma (PDAC). However, the clinical potential of targeting EphA2 requires further imaging evaluation. This study developed and preliminarily evaluated a novel 68Ga-labeled radiotracer for PET imaging of EphA2 expression in PDAC patients. METHODS: 68Ga-FZEAR-1, 68Ga-FZEAR-2, and 68Ga-FZEAR-3 were synthesized, and their stability, affinity, pharmacokinetics were evaluated in vitro and in vivo. Further biological evaluation was performed in EphA2-positive and EphA2-negative tumor xenografts. A pilot first-in-human PET/CT study of the lead candidate, 68Ga-FZEAR-2, was subsequently conducted in two PDAC patients. RESULTS: The three 68Ga-radiotracers were synthesized with high radiochemical purity (> 99%) and demonstrated high stability and nanomolar affinity for EphA2. Cellular uptake was consistent with EphA2 expression and blocking assays confirmed specificity. In vivo, all tracers exhibited high tumor accumulation with low off-target uptake. 68Ga-FZEAR-2 showed favorable tumor-targeting ability, pharmacokinetics, and safety profile. In the pilot clinical study (n = 2), 68Ga-FZEAR-2 PET/CT visualized primary and metastatic lesions clearly without adverse effects. Immunohistochemical analysis confirmed EphA2 expression in lesions exhibiting high tracer uptake. CONCLUSION: A series of 68Ga-labeled tracers for EphA2 imaging was successfully developed and evaluated. The lead candidate, 68Ga-FZEAR-2, showed promising targeting specificity and favorable pharmacokinetics. A pilot study indicated that 68Ga-FZEAR-2 provided preliminary evidence of noninvasive visualization of EphA2 expression in PDAC patients, thereby suggesting its potential as a tool for precision diagnosis in PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, EphA2Pancreatic NeoplasmsPositron Emission Tomography Computed TomographyRadiopharmaceuticalsCarcinoma, Pancreatic DuctalHumansAnimalsCell Line, TumorFemaleMiceMaleGallium RadioisotopesTissue DistributionPilot ProjectsRadioactive TracersMiddle Aged

Stichwörter der Autor:innen

EphA2 receptorPET/CT imagingPancreatic ductal adenocarcinomaPeptide radiopharmaceuticals

Substanzen

Receptor, EphA2Gallium RadioisotopesEPHA2 protein, humanRadiopharmaceuticalsRadioactive Tracers

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, No. 270 Dong'an Road, Xuhui District, Shanghai, 200032, China.
  • College of Chemistry and Materials Science, Shanghai Normal University, Shanghai, 200233, China.
  • Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Zhejiang International Cooperation Base of Biomedical Materials Technology and Application, Ningbo Cixi Institute of Biomedical Engineering, Zh…
  • Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, 200032, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
  • Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai, 200433, China.

Förderung

  • Shanghai Oriental Talents Program Youth Project
  • National Natural Science Foundation of China
  • Key Programme
  • Zhejiang Provincial Natural Science Foundation of China

Zitieren

APA

Liu, X., Sun, L., Lei, J., Bai, L., Guo, H., Fang, Y., Zhang, J., Jiang, C., Xu, X., & Song, S. (2026). Translation of a novel EphA2-targeted PET tracer from preclinical models to first-in-human studies in pancreatic cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-07966-4

Vancouver

Liu X, Sun L, Lei J, Bai L, Guo H, Fang Y, et al. Translation of a novel EphA2-targeted PET tracer from preclinical models to first-in-human studies in pancreatic cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-07966-4

BibTeX
@article{Liu2026,
  author = {Liu, Xinyu and Sun, Li and Lei, Jialiang and Bai, Liyan and Guo, Haoyao and Fang, Yichong and Zhang, Jianping and Jiang, Chunjuan and Xu, Xiaoping and Song, Shaoli},
  title = {Translation of a novel EphA2-targeted PET tracer from preclinical models to first-in-human studies in pancreatic cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-07966-4}
}
Kostenlos starten →